Simplifi 797 compounding compliance expert Annie Lambert, PharmD, BCSCP, recently discussed the proposed revisions to USP Chapters 795 and 797 and how your facility can prepare for enforcement.
This past September, the United States Pharmacopeia (USP) issued a long-awaited Notice of Intent to Revise (NITR) for both USP Chapter 795 and USP Chapter 797.
The United States Pharmacopeia (USP) Chapters <795> and <797> have been under review for the better part of a decade. The iterative process around updating the standards has led to unresolved guidance and confusion in the compounding community.
This webinar was designed to help you process these latest proposed September 1, 2021 revisions. Simplifi 797 compounding compliance expert, Annie Lambert, PharmD, BCSCP, will:
- Provide a summary of key changes in the newest revisions to both USP <795> and <797>.
- Give an update on issues discussed at the September stakeholder forums.
- Present action steps for assessing the potential impact on your compounding practice.
Simplifi 797 is a customizable, expert-developed automated solution that takes the effort out of USP <795>, <797>, and <800> compliance. Optimize your operations and pass inspections with the only closed-loop compliance support on the market. More than 2,000 pharmacies trust Simplifi 797 for compounding compliance confidence. Wolters Kluwer provides trusted clinical technology and evidence-based solutions that drive effective outcomes across healthcare. Specialized in clinical effectiveness, learning, research, and safety.
This post is related to:
IV/Infusion Resources/USP <797> Resources
